Article Information
History
- December 7, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Mark R Toshner1,
- Carrol Gamble2,
- J Kenneth Baillie3,
- Ashley Best2,
- Emma Bedson2,
- Judy Bradley4,
- Melanie Calvert5,
- Elin Haf Davies6,
- Annemarie B Docherty7,
- Efstathia Gkioni2,
- Dyfrig A Hughes8,
- Thomas Jaki9,
- R Gisli Jenkins10,
- Ashley Jones2,
- Martin J Landray11,
- Jonathan Mant1,
- Daniel F McAuley12,
- Peter JM Openshaw10,
- Duncan Richards11,
- Paul Wicks13,
- HEAL-COVID Collaboration and
- Charlotte Summers1,15,*
- 1University of Cambridge
- 2University of Liverpool
- 3Roslin Institute, University of Edinburgh
- 4Queen’s University, Belfast
- 5University of Birmingham
- 6Aparito Limited
- 7University of Edinburgh
- 8Bangor University
- 9MRC Biostatistics Unit, University of Cambridge
- 10Imperial College London
- 11University of Oxford
- 12Queen’s University Belfast
- 13Wicks Digital Health
- ↵*Correspondence to:
Prof Charlotte Summers and Dr Mark R Toshner, Heart and Lung Research Institute, University of Cambridge, Cambridge Biomedical Campus, Papworth Road, Cambridge, CB2 0BB United Kingdom, Email: trial.team{at}heal-covid.net
Posted December 07, 2022.
Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial
